Fundraising Fox

Kite Pharma

Santa Monica, US · Founded 2009 · 2 known investors

Find your way into Kite Pharma

65 people in our graph share verified history with the Kite Pharma team — schools, employers, funds. One of them is your warm intro.

Isabelle Smithunlockedknows Arie Belldegrun · together at Allogene Therapeutics
×10knows the team · via Vida Ventures
knows the team · via Kite Pharma

Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

BiotechHealthtech

Founders & leadership

Kite Pharma was founded in 2009 by Arie S. Belldegrun.

ASArie S. Belldegrun
Arie S. Belldegrunin𝕏Founder · ChairmanformerFounder and Senior Managing Director at Vida Ventures
MR
Margo R. RobertsExecutive
CBCynthia Butitta
Cynthia ButittainExecutive
MBMarc Better
Marc BetterinExecutive
RS
Rizwana SprouleinExecutive

Board

JA
Joshua A. KazamBoard director
DB
David BondermanBoard director
FC
Farah ChampsiBoard director
RN
Ran NussbaumBoard director
SB
Steven B. RuchefskyBoard director
RD
Roy DoumaniBoard director
JM
Jonathan M. PeacockBoard director

Investors · 2

Alta PartnersJackson · $1M – $12M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 2 rounds · 2014–2025

▶$50MraisedMay 2014 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy DoumaniDirector
  • Joshua A. KazamDirector
  • Margo R. RobertsExecutive Officer
  • Cynthia ButittaExecutive Officer
  • David BondermanDirector
  • Jonathan M. PeacockDirector
  • Arie S. BelldegrunExecutive Officer, Director
  • Marc BetterExecutive Officer
  • Farah ChampsiDirector
  • Ran NussbaumDirector
  • Steven B. RuchefskyDirector
  • Rizwana SprouleExecutive Officer
  • Keith NolopExecutive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Kardigan raises $254M, Kezar plans layoffs, Kite and Pregene ink $1.52B cell therapy deal | Partnologypartnology.com · Oct 2025Kite Pharma Raises $35M Series A Fundingleadsontrees.com · Sep 2025Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&Aforbes.com · Jan 2018Fledgling cancer vax biotech raises $15M in Series A | Fierce Biotechfiercebiotech.com · Mar 2011Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors | Business Wirebusinesswire.com · Mar 2011

Frequently asked questions

What does Kite Pharma do?
Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Who founded Kite Pharma?
Kite Pharma was founded by Arie S. Belldegrun in 2009.
Who are Kite Pharma's investors?
Kite Pharma's investors include Alta Partners, Pontifax Venture Capital.
How much funding has Kite Pharma raised?
Kite Pharma has disclosed $50M raised across 1 of its 2 known rounds.
Where is Kite Pharma headquartered?
Kite Pharma is headquartered in Santa Monica, US.